Navigation Links
Galderma Launches New Cetaphil(R) SPF 50 Product
Date:2/17/2009

Top Skin Care Brand is Taking Facial Sun Protection to a New Level

FORT WORTH, Texas, Feb. 17 /PRNewswire/ -- Galderma Laboratories is excited to introduce a NEW SPF 50 facial moisturizer from Cetaphil(R), the #1 dermatologist-recommended brand of cleansers and moisturizers, that provides broad spectrum protection. Finally, a product that goes beyond moisturizing, to provide the highest SPF available for a moisturizer designed specifically for the face. Cetaphil(R) UVA/UVB Defense SPF 50 is non-greasy; it nourishes and hydrates skin, while protecting it from the sun's harmful rays.

Cetaphil(R) UVA/UVB Defense SPF 50 delivers across the spectrum to help protect skin from UVA/UVB rays, and help hydrate as a daily facial moisturizer. It contains an optimum blend of 4 filters and micronized Titanium Dioxide that screen both the UVA and UVB rays. For patients requiring an effective sunscreen as part of the management of their skin related condition, Cetaphil(R) UVA/UVB Defense SPF 50 combines two steps in one making it an ideal choice for both daily sun protection and for moisturizing the face.

Cetaphil(R) UVA/UVB Defense SPF 50 has also been awarded the Skin Cancer Foundation Seal of Recommendation. The Skin Cancer Foundation recommends this product as an effective UV facial sunscreen and as an effective aid in the prevention of sun induced damage to the skin including sunburn and possibly, premature aging. It is important to use proper UVA/UVB filters to help prevent sunburn and other skin damage.

The lightweight formula of the Cetaphil(R) UVA/UVB Defense SPF 50 hydrates the skin to avoid evaporation and absorbs quickly, leaving no filmy white residue. It is fragrance free, non-irritating and non-comedogenic, so it won't clog pores, making it a suitable choice for those with acne, rosacea or melasma and other skin related conditions, where a hydrating formula with SPF protection is recommended.

Cetaphil(R) UVA/UVB Defense SPF 50 is available in a 1.7 oz. tube for $13.99 and is available at major retail, grocery and drug stores nationwide.

For more information about Cetaphil(R) products or to join the Cetaphil(R) Skin Care Club, visit www.cetaphil.com.

About Galderma

Galderma, created in 1981 as a joint venture between Nestle and L'Oreal, is a fully-integrated specialty pharmaceutical company dedicated exclusively to the field of dermatology. The Company is committed to improving the health of skin with an extensive line of products across the world that treat a range of dermatological conditions. With a research and development center in Sophia Antipolis, France, Galderma has one of the largest R&D facilities dedicated exclusively to dermatology. Leading worldwide dermatology brands include Differin(R), MetroGel(R) 1%/Rozex(R), Clobex(R), Tri-Luma(R), Loceryl(R) and Cetaphil(R).

For more information on Galderma, visit www.galdermaUSA.com.

About Cetaphil

The Family of Cetaphil(R) Cleansers and Moisturizers is a line of dermatologist-recommended skin care products specially formulated for all skin types and conditions. Cetaphil(R) products are developed to provide effective, gentle skin care and include: Cetaphil(R) Gentle Skin Cleanser, Cetaphil(R) Daily Facial Cleanser, Cetaphil(R) Gentle Cleansing Bar, Cetaphil(R) Antibacterial Gentle Cleansing Bar, Cetaphil(R) Moisturizing Lotion, Cetaphil(R) Moisturizing Cream, Cetaphil(R) DailyAdvance Ultra Hydrating Lotion, Cetaphil(R) Daily Facial Moisturizer SPF 15, Cetaphil(R) Therapeutic Hand Cream.

To learn more about Cetaphil(R) products and to join the Cetaphil(R) Skin Care Club visit www.cetaphil.com


'/>"/>
SOURCE Galderma Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis
2. Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne
3. Galderma announces approval for Differin gel 0.1 percent in Japan
4. Galderma Completes Tender Offer for CollaGenex
5. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
6. ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic
7. Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
8. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
9. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
10. Crossover Health Launches Personal Health Advisory Service
11. Photos: Medpedia Launches
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 24, 2017 , ... The California State University Institute for Palliative Care ... or interested in palliative care education and research. The Symposium, “Innovate. Investigate. Educate: ... San Diego on Sept. 28 and 29, 2017, on the campus of California State ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders Professionals ... What You See” body image mannequin art competition. Selected from 15 submissions from around ... winner revealed at the 31st annual iaedp Symposium, March 22 – 26 in Las ...
(Date:2/24/2017)... ... 2017 , ... The Radiology Business Management Association will select the ... annual Building Better Radiology Marketing Programs conference, held this year from March ... Nine awards are given out in five categories. They are:, , ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... Senior International Elite division on February 12th. Ms. Esparza qualified into this ... elite qualifier competition held in Las Vegas, Nevada. Frida is one of approximately ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the ... The Jensie Gran Fondo of Marin. For the second year in a row, ... mineral-based sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 Nevro Corp. (NYSE: NVRO), a global medical ... treatment of chronic pain, today reported financial results for the ... 2016 Accomplishment & Highlights: Achieved ... increase of 228% as reported, over the prior year ... of 612% over the prior year International ...
(Date:2/23/2017)... Research and Markets has announced the addition of the "Oesophageal ... their offering. ... The latest research Oesophageal Cancer Drugs Price Analysis and Strategies - ... Cancer market. The research answers the following questions: ... Oesophageal Cancer and their clinical attributes? How are they positioned in ...
(Date:2/23/2017)... 23, 2017 Regulus Therapeutics Inc . ... development of innovative medicines targeting microRNAs, today announced it ... results on Thursday, March 2, 2017 after the market ... and webcast on March 2, 2017 at 5:00 p.m. ... 2016 financial results and provide a general business update.  ...
Breaking Medicine Technology: